XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Note 19 - Segment Reporting
9 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 19 - Segment Reporting

 

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on the Company’s financial information. The CODM reviews financial information presented for each reportable segment for the purpose of making operating decisions and assessing financial performance.

 

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Rx and Consumer Health. The Rx Segment consists of the Company’s prescription products. The Consumer Health Segment contains the Company’s consumer healthcare products. For purposes of determining operating income or loss by segment, the Company allocates common expenses such as corporate administration, executive and board compensation, insurance, and fees associated with being a publicly traded entity, among others, to the Rx Segment. The Rx Segment also includes pipeline research and development. The CODM does not regularly review asset information by segment, accordingly, asset information is not provided by segment.

 

Select financial information for these segments is as follows:

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Three Months Ended March 31, 2024

            
             

Net revenue

 $14,025  $3,968  $17,993 

Loss from operations

 $(1,598) $(866) $(2,464)
             

Depreciation and amortization

 $1,449  $385  $1,834 

Stock-based compensation expense

 $699  $112  $811 
             

Three Months Ended March 31, 2023

            
             

Net revenue

 $13,805  $8,928  $22,733 

Loss from operations

 $(7,122) $(1,436) $(8,558)
             

Depreciation and amortization

 $1,563  $280  $1,843 

Stock-based compensation expense

 $788  $114  $902 

 

  

Rx

  

Consumer Health

  

Consolidated

 
  

(in thousands)

 

Nine Months Ended March 31, 2024

            
             

Net revenue

 $50,590  $12,436  $63,026 

Income (loss) from operations

 $682  $(2,286) $(1,604)
             

Depreciation and amortization

 $4,513  $1,161  $5,674 

Stock-based compensation expense

 $2,131  $430  $2,561 
             

Nine Months Ended March 31, 2023

            
             

Net revenue

 $50,486  $26,181  $76,667 

Loss from operations

 $(13,579) $(3,655) $(17,234)
             

Depreciation and amortization

 $4,709  $842  $5,551 

Impairment expense

 $2,600  $  $2,600 

Stock-based compensation expense

 $4,937  $209  $5,146